Title:
THYROID HORMONE RECEPTOR AGONISTS
Document Type and Number:
WIPO Patent Application WO/2020/073974
Kind Code:
A1
Abstract:
Provided herein are novel thyroid hormone receptor (TR) agonists, e. g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.
More Like This:
Inventors:
DAI XING (CN)
WANG YAOLIN (CN)
JIANG YUEHENG (CN)
LIU YANQIN (CN)
HAN ZIXING (CN)
WANG ZHENWU (CN)
TAO LIANGSHAN (CN)
SHI ZHE (CN)
WANG YAOLIN (CN)
JIANG YUEHENG (CN)
LIU YANQIN (CN)
HAN ZIXING (CN)
WANG ZHENWU (CN)
TAO LIANGSHAN (CN)
SHI ZHE (CN)
Application Number:
PCT/CN2019/110494
Publication Date:
April 16, 2020
Filing Date:
October 11, 2019
Export Citation:
Assignee:
INVENTISBIO SHANGHAI LTD (CN)
International Classes:
C07D403/12; A61K31/53; A61P5/16
Domestic Patent References:
| WO2007009913A1 | 2007-01-25 | |||
| WO2014043706A1 | 2014-03-20 | |||
| WO2009037172A1 | 2009-03-26 |
Foreign References:
| EP1471049A1 | 2004-10-27 |
Other References:
KELLY M.ET AL.: "Discovery of 2‑[3，5-Dichloro-4-(5-isopropyl-6-oxo-1，6-dihydropyridazin-3-yloxy)phenyl]-3，5-dioxo-2，3，4，5-tetrahydro[1，2，4]triazine-6-carbonitrile (MGL-3196)， a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 8 April 2014 (2014-04-08), pages 3912 - 3923, XP055436939, DOI: 20191230165242
See also references of EP 3864013A4
See also references of EP 3864013A4
Attorney, Agent or Firm:
KINGSOUND & PARTNERS (CN)
Download PDF: